The short version of incretin receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-20. Anything still debated is marked as such rather than presented as settled.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
=== Vitrification === Vitrification is a flash-freezing (ultra-rapid cooling) process that helps to prevent the formation of ice crystals and helps prevent cryopreservation damage. Researchers Greg Fahy and William F. Rall helped to introduce vitrification to reproductive cryopreservation in the mid-1980s. As of 2000, researchers claim vitrification provides the benefits of cryopreservation without damage due to ice crystal formation. The situation became more complex with the development of tissue engineering as both cells and biomaterials need to remain ice-free to preserve high cell viability and functions, integrity of constructs and structure of biomaterials. Vitrification of tissue engineered constructs was first reported by Lilia Kuleshova, who also was the first scientist to achieve vitrification of oocytes, which resulted in live birth in 1999. For clinical cryopreservation, vitrification usually requires the addition of cryoprotectants before cooling. Cryoprotectants are macromolecules added to the freezing medium to protect cells from the detrimental effects of intracellular ice crystal formation or from the solution effects, during the process of freezing and thawing. They permit a higher degree of cell survival during freezing, to lower the freezing point, to protect cell membrane from freeze-related injury. Cryoprotectants have high solubility, low toxicity at high concentrations, low molecular weight and the ability to interact with water via hydrogen bonding. Instead of crystallizing, the syrupy solution becomes an amorphous ice—it vitrifies.
United States: The U.S. government operates border preclearance facilities at several ports and airports in foreign territory. They are staffed and operated by U.S. Customs and Border Protection officers. Travellers pass through the U.S. Immigration and Customs, Public Health, and Agriculture inspections before boarding their aircraft, ship, or train. This process is intended to streamline border procedures, reduce congestion at ports of entry, and facilitate travel between the preclearance location and American airports that are not equipped to handle international travellers. These facilities are present at the majority of major Canadian airports, as well as selected airports in Bermuda, Aruba, the Bahamas, Abu Dhabi and Ireland. Facilities located in Canada accept NEXUS cards and United States Passport cards (land/sea entry only) in place of passports. A preclearance facility is currently being planned at Dubai International Airport. Citizens of the Bahamas who enter United States through either of the two preclearance facilities in that country enjoy an exemption from the general requirement to hold a visa as long as they can sufficiently prove that they do not have a significant criminal record in either the Bahamas or the U.S. All Bahamians applying for admission at a port-of-entry other than the preclearance facilities located in Nassau or Freeport International airports are required to have a valid visa. Preclearance facilities are also operated at Pacific Central Station, the Port of Vancouver, and the Port of Victoria in British Columbia.
Indoor air quality (IAQ) is the air quality within buildings and structures. Poor indoor air quality due to indoor air pollution is known to affect the health, comfort, and well-being of building occupants. It has also been linked to sick building syndrome, respiratory issues, reduced productivity, and impaired learning in schools. Common pollutants of indoor air include secondhand tobacco smoke, air pollutants from indoor combustion, radon, molds and other allergens, carbon monoxide, volatile organic compounds, legionella and other bacteria, asbestos fibers, carbon dioxide, ozone and particulates. Source control, filtration, and the use of ventilation to dilute contaminants are the primary methods for improving indoor air quality. Although ventilation is an integral component of maintaining good indoor air quality, it may not be satisfactory alone. In scenarios where outdoor pollution would deteriorate indoor air quality, other treatment devices such as filtration may also be necessary. IAQ is evaluated through collection of air samples, monitoring human exposure to pollutants, analysis of building surfaces, and computer modeling of air flow inside buildings. IAQ is part of indoor environmental quality (IEQ), along with other factors that exert an influence on physical and psychological aspects of life indoors (e.g., lighting, visual quality, acoustics, and thermal comfort). Indoor air pollution is a major health hazard in developing countries and is commonly referred to as "household air pollution" in that context.
=== Chinese industry === The State Council ordered the testing of product of all dairy producers, and to this end, some 5,000 inspectors were dispatched. The Chinese market has grown at an average annual rate of 23% since 2000. In 2006, milk production reached 30 million tons, ten times the volume of a decade before. It was valued at some ¥122 billion (US$18 billion) in 2007, and consumers had severely lost confidence in the industry. The events have exposed the often-incestuous relationship between local business and local government. In addition to the tax revenues to local authorities—Sanlu contributed ¥330 million in 2007, many companies invite local officials to become "silent partners" in their corporations—in return for "protection" at the political level; former Sanlu chairman Tian Wenhua was made honorary deputy to the Provincial People's Congress. The scandal has also highlighted structural problems of inadequate production volume, inherent quality issues, and poor production methods. The Inner Mongolia region produces over one-fourth of China's milk, and Mengniu and Yili have invested millions to establish state-of-the-art dairy facilities in its capital, Hohhot. The companies still rely on small-scale farmers for over 90% of their production because of the capacity constraint of the modern facilities. Both companies were said by farmers and agents to have habitually purchased milk which failed quality tests, for only two-thirds the normal price. A new policy was put in place on 17 September to stop that practice.
Sources: en.wikipedia.org
Rourk's legislative platform emphasizes economic stability for working families, advocating for strengthening the Child Tax Credit, expanding technical workforce training and apprenticeships, and indexing the federal minimum wage to the cost of living. On healthcare, she favors a public option, permanently expanding Affordable Care Act (ACA) subsidies, and allowing Medicare to negotiate prescription drug price. Her broader policy priorities include fully funding public schools while opposing private school voucher expansions, establishing a federal accountability framework for AI data center infrastructure, and passing comprehensive immigration reform that combines border enforcement with an earned path to citizenship for law-abiding residents.
=== Forensic and archaeological === Blood residue can help forensic investigators identify weapons, reconstruct a criminal action, and link suspects to the crime. Through bloodstain pattern analysis, forensic information can also be gained from the spatial distribution of bloodstains. Blood residue analysis is also a technique used in archeology.
Tandem mass spectrometry, also known as MS/MS or MS2, is a technique in instrumental analysis where two or more stages of analysis using one or more mass analyzers are performed with an additional reaction step in between these analyses to increase their abilities to analyse chemical samples. A common use of tandem MS is the analysis of biomolecules, such as proteins and peptides. The molecules of a given sample are ionized and the first spectrometer (designated MS1) separates these ions by their mass-to-charge ratio (often given as m/z or m/Q). Ions of a particular m/z-ratio coming from MS1 are selected and then made to split into smaller fragment ions, e.g. by collision-induced dissociation, ion-molecule reaction, or photodissociation. These fragments are then introduced into the second mass spectrometer (MS2), which in turn separates the fragments by their m/z-ratio and detects them. The fragmentation step makes it possible to identify and separate ions that have very similar m/z-ratios in regular mass spectrometers.
The violence began on 11 July, after a Druze vegetable merchant was assaulted by members of Bedouin tribes after they set up an improvised roadblock. The Bedouin attackers subjected him to sectarian insults and repeated death threats during his detention. He was later released to a remote village while blindfolded and in critical condition. In response, local Druze armed groups detained several individuals from Bedouin tribes the next day in an effort to recover the stolen property. This initiated a cycle of retaliatory kidnappings between the two sides, which quickly escalated into open armed clashes. On 13 July, the Bedouin fighters responded by establishing a checkpoint in the al-Maqwas neighborhood in eastern Suwayda city, where they captured several members of the local Druze armed groups. Armed clashes soon erupted between the two sides in and around the area, the clashes spread to at-Tira, al-Mazraa, and as-Sawra al-Kabira. Bedouins from Daraa Governorate arrived to the area to assist the Bedouin fighters. On 14 July, video was released showing a General Security vehicle, including a person making sectarian statements, declaring his participation in the conflict.
Samples are transported daily to the laboratory responsible for testing. In the United States and Canada, newborn screening is mandatory, with an option for parents to opt out of the screening in writing if they desire. In many regions, NBS is mandatory, with an option for parents to opt out in writing if they choose not to have their infant screened. In most of Europe, newborn screening is done with the consent of the parents. Proponents of mandatory screening claim that the test is for the benefit of the child, and that parents should not be able to opt out on their behalf. In regions that favour informed consent for the procedure, they report no increase in costs, no decrease in the number of children screened and no cases of included diseases in children who did not undergo screening.
Sources: en.wikipedia.org
=== Vaccine development and advance market commitments === Advance Market Commitments (AMCs) aim to overcome market failure by making an advance pledge that if a vaccine for a certain condition is developed, meeting certain specifications, donors will buy a certain number of doses. Gavi seeks to design its AMCs in a way that encourages a competitive market. Gavi has been particularly successful at promoting the uptake of newer vaccines.
=== Environmental and physical factors === Susceptibility to vitiligo appears to be affected by region, especially early in life (e.g. a lack of exposure to microbes weakening the immune system). Most cases seem to start before the age of 20. An event like a sunburn, exposure to toxins, stress or emotional distress can trigger and/or exacerbate the condition. Existing cases of vitiligo may also be aggravated by temperature changes (causing dryness or sweating), poor hydration, or unprotected sun exposure. Skin depigmentation can occur at the site of physical trauma, an example of the Koebner phenomenon; unlike in other skin diseases, this can be caused by daily activities, especially chronic friction on particular areas of the body. The phenomenon occurs in a third of patients with NSV but is rarely seen in SV. Vitiligo may be a multifactorial disease, with environmental factors triggering preexisting genetic susceptibilities.
=== Anaesthesia === Labial reduction can be performed under local anaesthesia, conscious sedation, or general anaesthesia, either as a discrete, single surgery, or in conjunction with another, gynecologic or cosmetic, surgery procedure. The resection proper is facilitated with the administration of an anaesthetic solution (lidocaine + epinephrine in saline solution) that is infiltrated to the labia minora to achieve the tumescence (swelling) of the tissues and the constriction of the pertinent labial circulatory system, the hemostasis that limits bleeding.
=== Test patch for child food allergies === The team from DBV Technologies has developed a patented, innovative process, the E-Patch, which is used to determine allergies in children. The ready-to-use, standardised patch tests are highly reliable and conserve the allergic agents in their optimal state. This innovative technique uses the principal of freeze drying and electrification to retain the allergic agents on the patch, without using solvent or glue. The E-patch is then conditioned so that it remains air and water tight. Once applied to the child the allergic agents are rapidly hydrated by body transpiration and liberated from the patch. They enter into contact with the skin and create, if positive, a reaction which can be seen by the doctor 48 hours later.
=== Airspace restrictions === The Swiss Federal Council approved temporary restrictions on airspace in the Lake Geneva region from 10 to 18 June 2026. The restrictions applied to visual flight traffic and non-commercial instrument flight traffic in an area centred on Évian, Lausanne and Geneva Airport. The Swiss Air Force, the Geneva cantonal police and the French Air and Space Force were responsible for reinforced airspace surveillance and air policing.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.